The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
HER2 heterogeneity as a predictor of response to neoadjuvant T-DM1 plus pertuzumab: Results from a prospective clinical trial.
 
Otto Metzger Filho
Honoraria - Grupo Oncoclinicas; Roche
Research Funding - Abbvie (Inst); Cascadian Therapeutics (Inst); Eisai (Inst); Pfizer (Inst); Roche/Genentech (Inst); Susan G. Komen for the Cure (Inst)
Travel, Accommodations, Expenses - Grupo Oncoclinicas
 
Giuseppe Viale
Honoraria - MSD Oncology; Pfizer
Consulting or Advisory Role - Astellas Pharma; Dako; Novartis; Roche/Genentech
Research Funding - Dako/Agilent Technologies (Inst); Roche/Genentech; Ventana Medical Systems (Inst)
Travel, Accommodations, Expenses - Celgene; Roche; Roche
 
Lorenzo Trippa
No Relationships to Disclose
 
Tianyu Li
No Relationships to Disclose
 
Denise A. Yardley
Consulting or Advisory Role - Biotheranostics (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Daiichi Sankyo/Lilly (Inst); Eisai (Inst); Genentech/Roche (Inst); NanoString Technologies (Inst); Novartis (Inst)
Speakers' Bureau - Genentech/Roche; Genentech/Roche; Novartis
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Clovis Oncology (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Genentech/Roche (Inst); Immunomedics (Inst); InventisBio (Inst); Lilly (Inst); Macrogenics (Inst); MedImmune (Inst); Medivation (Inst); Merck (Inst); Novartis (Inst); Oncothyreon (Inst); Pfizer (Inst); Syndax (Inst); Tesaro (Inst)
Travel, Accommodations, Expenses - Genentech/Roche; Novartis
 
Ingrid A. Mayer
Consulting or Advisory Role - AstraZeneca; Genentech; GlaxoSmithKline; Immunomedics; Lilly; Macrogenics; Novartis
Research Funding - Genentech (Inst); Novartis (Inst); Pfizer (Inst)
 
Vandana Gupta Abramson
Consulting or Advisory Role - Eisai; Novartis
Research Funding - Astellas Pharma; Genentech/Roche; Lilly
 
Carlos L. Arteaga
Leadership - American Association for Cancer Research
Stock and Other Ownership Interests - Provista Diagnostics
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; KIYATEC; Lilly; Monogram Biosciences; Novartis; Roche; Seragon; Susan G. Komen for the Cure
Research Funding - AstraZeneca; Novartis; Puma Biotechnology; U3Pharma
 
Laura Spring
Honoraria - Dava Oncology
Consulting or Advisory Role - Novartis
Research Funding - Tesaro (Inst)
Travel, Accommodations, Expenses - Novartis
 
Adrienne Gropper Waks
No Relationships to Disclose
 
Michalina Janiszewska
No Relationships to Disclose
 
Eileen Wrabel
No Relationships to Disclose
 
Michelle Demeo
No Relationships to Disclose
 
Aditya Bardia
Consulting or Advisory Role - bioTheranostics; Genentech; Genentech/Roche (Inst); Immunomedics; Immunomedics; Immunomedics (Inst); Innocrin Pharma (Inst); Merck; Merck (Inst); Novartis; Novartis (Inst); Pfizer; Pfizer (Inst); Radius Health; Radius Health (Inst); Sanofi; Spectrum Pharmaceuticals
Research Funding - bioTheranostics
 
Tari A. King
Honoraria - Genomic Health
 
Kornelia Polyak
Honoraria - Genentech
Consulting or Advisory Role - Mitra Biotech
Research Funding - Novartis
Patents, Royalties, Other Intellectual Property - Patents on S100A7 antibody and BET inhibitor resistance
 
Eric P. Winer
Stock and Other Ownership Interests - Verastem
Honoraria - Carrick Therapeutics; Genentech/Roche; GlaxoSmithKline; InfiniteMD; Jounce Therapeutics; Jounce Therapeutics; Lilly; Tesaro
Consulting or Advisory Role - InfiniteMD; Leap Therapeutics
Research Funding - Genentech (Inst)
 
Ian E. Krop
Employment - AMAG Pharmaceuticals (I)
Leadership - AMAG Pharmaceuticals (I)
Stock and Other Ownership Interests - AMAG Pharmaceuticals (I)
Honoraria - Genentech/Roche
Consulting or Advisory Role - Context Therapeutics; Daiichi Sankyo; Genentech/Roche; Macrogenics; Seagen; Taiho Pharmaceutical
Research Funding - Genentech (Inst); Pfizer (Inst)